News
10-12-2011, 02:54 AM
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
More... (http://www.news-medical.net/news/20111012/FDA-grants-Advaxis-pre-IND-meeting-for-ADXS-HER2-immunotherapy.aspx)
More... (http://www.news-medical.net/news/20111012/FDA-grants-Advaxis-pre-IND-meeting-for-ADXS-HER2-immunotherapy.aspx)